Novartis’ Lucentis Receive EU’s CHMP Positive Opinion for Retinopathy of Prematurity in Preterm Infants

 Novartis’ Lucentis Receive EU’s CHMP Positive Opinion for Retinopathy of Prematurity in Preterm Infants

Novartis’ Lucentis Receive EU’s CHMP Positive Opinion for Retinopathy of Prematurity in Preterm Infants

Shots:

  • The EMA’s CHMP has recommended the approval of Lucentis (ranibizumab, 10 mg/ml) for the treatment of ROP in preterm infants with EC’s anticipated decision within three months
  • The submission is based on P-III RAINBOW study results demonstrating Lucentis is safe & well tolerated in infants with ROP. Post-EU approval, Lucentis (0.2 mg) will be indicated for the treatment of preterm infants with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP disease
  • Lucentis is an anti-VEGF therapy, act by destroying the tissue in the eye responsible for the elevation of VEGF and developed by Genentech & Novartis with its US rights belonging to Genentech and ROW rights to Novartis

Click here to­ read full press release/ article | Ref: Novartis | Image: Chicago Tribune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post